Autologous tolerogenic dendritic cells (ATDC) for highly sensitized kidney transplant recipients

2024-519978-39-00 Protocol ATDC-PICI Human pharmacology (Phase I) - Other Ongoing, recruitment ended

Start 17 Apr 2026 · Status Ongoing, recruitment ended · 1 EU/EEA countries · 7 sites · Protocol ATDC-PICI

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruitment ended
Participants planned 30
Countries 1
Sites 7

Kidney trasplants

Key facts

Sponsor
Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer
Participant type
Patients
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Phenomena and Processes [G] - Reproductive and Urinary Physiological Phenomena [G08]
Trial duration
17 Apr 2026 → ongoing
Decision date (initial)
2025-05-16
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Kidney trasplants

VersionLevelCodeTermSystem organ class
20.0 LLT 10023438 Kidney transplant 10042613

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer

Sponsor organisation
Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer
Address
Calle Rosellon 149-153
City
Barcelona
Postcode
08036
Country
Spain

Scientific contact point

Organisation
Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer
Contact name
Dr Fritz Diekmann

Public contact point

Organisation
Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer
Contact name
Dr Fritz Diekmann

Locations

1 EU/EEA country · 7 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Ongoing, recruitment ended 30 7
Rest of world 0

Investigational sites

Spain

7 sites · Ongoing, recruitment ended
Fundacio Puigvert
Nephrology, Calle De Cartagena 340-350, 08025, Barcelona
Hospital Clinic De Barcelona
Nephrology and Kidney Transplantation, Calle Villarroel 170, 08036, Barcelona
Hospital Germans Trias I Pujol
KIDNEY AND PANCREAS TRASPLANT UNIT, Carretera Canyet 1a Planta, 08916, Badalona
Hospital Universitario Miguel Servet
Nephrology, Paseo De Isabel La Catolica 1-3, 50009, Zaragoza
Hospital Universitari Vall D Hebron
Nephrology, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona
Bellvitge University Hospital
Nephrology and Renal Transplantation, Carrer De La Feixa Llarga S/N, 08907, L'Hospitalet De Llobregat
Hospital Del Mar
Nephrology, Passeig Maritim De La Barceloneta 25-29, 08003, Barcelona

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Spain 2025-06-25 2025-06-25 2025-12-31

Oversight and notifications

Regulatory notifications under CTR Articles 38, 52, 53, 54 and 77

Temporary halts 1 · Art. 38 CTR

Temporary halt TH-114958

Halt date
2025-12-31
Planned restart
2026-02-20
Member states concerned
Spain
Publication date
2026-01-15
Reason
Safety related (clinical or pre-clinical results)
Explanation
After the notification of the exitus of two patients who had received study treatment the study was halted (recruitment and treatment). The Sponsor considers it appropriate to perform a safety analysis before administration of the investigational product to any additional patients.
Follow-up measures
Apart from the two cases with fatal outcomes, no other patient enrolled in the study has received the treatment to date. In the event that a transplant alarm is triggered for a patient already enrolled in the clinical trial, it is proposed that the transplant be performed in accordance with the center’s standard clinical criteria; however, the investigational product would not be administered.
A DSMB meeting will be convened as soon as possible in order to evaluate the events. Clinical
information about the patients and all safety information will be provided for the meeting.
Benefit-risk balance changed
Yes
Treatment stopped
Yes

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-02-13 Spain Acceptable
2025-05-05
2025-05-16
2 SUBSTANTIAL MODIFICATION SM-2 2026-03-19 Spain Acceptable 2026-04-16